DV 1179 / Dynavax - LARVOL DELTA

Advances and challenges in Toll-like receptor-targeted therapy for rheumatoid arthritis. (PubMed, Drug Discov Today) - "Representative agents such as OPN-305, OPN-301, imiquimod, and antidepressants have demonstrated therapeutic potential by modulating TLR signaling in RA pathological manifestations. TollB-001, a novel small molecular drug, represents a potential breakthrough in RA therapy. Despite promising preclinical and clinical outcomes with agents including IMO-3100, DV-1179, and R848, challenges remain regarding efficacy variability and immune-related safety. This review aims to provide insights into TLR-based interventions and inform the development of future strategies for more effective management."

Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. (PubMed, Biomedicines) - "Despite the consistent success of selective inhibition of TLR ligation in animal models, DV-1179 (dual TLR7/9 antagonist) failed to achieve pharmacodynamic effectiveness in SLE, and NI-0101 (mAb against TLR4) failed to improve arthritis in RA...Small molecules inhibiting shared kinases involved in TLR signaling and peptidomimetics disrupting the assembly of common signalosomes ("Myddosome") are under development. Targeted degraders (proteolysis-targeting chimeras (PROTACs)) of intracellular molecules involved in TLR signaling are a new class of TLR inhibitors with promising preliminary data awaiting further clinical validation."

Journal • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Targeted Protein Degradation • TLR4

Dynavax: Annual Report 2013 (Dynavax) - Anticipated completion of P1 trial for SLE in H2 2014 

Anticipated trial completion date • Lupus

Dynavax reports second quarter 2014 financial results and safety and pharmacodynamic results for asthma and lupus drug candidates (Market Watch) - P1b/2a, N=52; "DV1179 did not meet the primary or secondary pharmacodynamic endpoints related to reduction in interferon alpha-regulated genes. Doses up to 60 mg/week for 8 weeks were well tolerated. The most common adverse events were injection site reactions. GlaxoSmithKline will review the data package and determine whether to exercise its option to license DV1179."

P1/2 data • Lupus